ERBB2 and neoplasm: Present experimental data offered in this study suggests that the described humanized anti-HER3 mAbs could overcome resistance of progressive cancers to HER1- or HER2-directed therapies, as suggested by enhanced anti-tumor effect with elrotinib (Figure 7E).